secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARROW, INC. (HROW)
CIK:        0001360214
Form:       8-K
Filed at:   2026-10-05T11:32:18+00:00
Accession:  0001628280-26-064749
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 2.01, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Harrow closes $30M cash acquisition of TYRVAYA from Viatris, up to $70M in sales milestones
--------------------------------------------------------------------------------

- Paid Viatris $30.0M cash at closing, funded with cash on hand; up to $70M in contingent milestones tied to TYRVAYA net sales through Dec 31, 2029; total potential consideration $100M.
- Harrow acquired worldwide TYRVAYA rights except Japan; Viatris kept Japan commercialization rights and will pay Harrow tiered royalties on Japanese net sales.
- TYRVAYA is the first and only FDA-approved nasal spray for dry eye disease; approved in U.S., China and Taiwan, with marketing applications pending in additional markets.
- About 40 experienced Viatris personnel with TYRVAYA and dry eye knowledge are expected to join Harrow's Ocular Surface commercial team in Q4 2026.
- Harrow expects TYRVAYA to contribute more than $30 million in revenue in 2027; product complements VEVYE in the dry eye franchise and both use PhilRx pharmacy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1360214/000162828026064749/0001628280-26-064749-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1360214/000162828026064749/hrow-20261001.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-064749

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer